Novo Nordisk AS of Denmark has underscored its ambitions to find anti-obesity therapies by inking an R&D collaboration with Danish biotech Embark Biotech ApS which will focus on the discovery of novel treatments for the condition and its associated metabolic pathologies through mechanisms in the body that increase energy expenditure.
Novo Nordisk, Embark Seek Obesity Drugs That Boost Body's Energy Use
Danish duo enter pact to discover novel therapeutics for obesity and related metabolic diseases using mechanisms that increase the body's expenditure of energy.
More from Business
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.